Ignyta Names Senior VP, Chemistry & Manufacturing
This article was originally published in Scrip
Ignyta, Inc., a precision oncology biotechnology company, has appointed Dr Valerie Harding to the newly created role of senior vice-president, chemistry, manufacturing, and controls. Harding joins Ignyta from Pfizer, where she held many roles including vice-president of product differentiation, vice-president of drug product design and vice-president of pharmaceutical development. Prior to Pfizer, Harding spent three years as a scientist and team leader at Boots and Company, preceded by three years as a tutor and researcher at the University of Nottingham's School of Pharmacy. Harding holds a Ph.D. in Pharmaceutical Microbiology from the University of Nottingham and a B.S. in Pharmacy from the University of London.
You may also be interested in...
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.
A selection of articles you might have missed from August 2020, including exclusive interviews with industry leaders and a review of financing trends.
Rabia Khan, managing director of discovery sciences at Sensyne Health, talks to In Vivo about pairing biology with technology in the most effective way, managing COVID-19 challenges and what the future leaders of biopharma might look like.